Adrian M Di Bisceglie

10PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyMolecular targetsMedical biochemistry - lipidsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 04, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Anna Fettiplace, Arie Regev, Alexandre Kiazand

|Feb 13, 2025
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling.

Amrik Shah, Leigh MacConell, Alexander Liberman

|Sep 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.

Anna Fettiplace, John Marcinak, Michael Merz

|Mar 08, 2023
Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.

David E Kleiner, Mauricio Lisker-Melman, Abdus S Wahed

|Sep 18, 2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.

Stephen A Harrison, Nadege Gunn, Guy W Neff

|Nov 13, 2020
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.

Adrian M Di Bisceglie, Gerald F Watts, Philip Lavin

Pageof 2

Frequent Collaborators

2 joint publications

Anna Fettiplace

2 joint publications

Arie Regev

2 joint publications

Hans Tillmann

1 joint publications

Mandana Khalili